Long-Term Outcomes of Pegcetacoplan for GA Show Promise

Results of the 30-month data cut of the 3-year GALE open-label extension trial of pegcetacoplan for geographic atrophy showed that the drug produced clinically meaningful reductions in lesion growth.

Related Keywords

Washington ,United States ,Seattle ,California ,American ,Roger Goldberg ,American Society Of Retina Specialists ,Bay Area Retina Associates In Pleasanton ,Apellis Pharmaceuticals ,American Society ,Bay Area Retina Associates ,Retina Specialists ,Presented July ,Exudative Age Related Macular Degeneration ,Xudative Armd ,Phakic Iol ,Phakic Intraocular Lens ,Hakic Intraocular Lens Implant ,Hakic Iol Implant ,Retinal Disease ,Vision Care And Maintenance ,Retina ,Uveitis ,Vasculitis ,Intraocular Inflammation ,Eye ,Optic Neuropathy ,Corneal Disease ,Endophthalmitis ,Fundus ,Macular Degeneration ,Ge Related Macular Degeneration Armd ,Neuropathy ,Optic Disk ,Vegf Vascula ,